Sr One

Sr One

A venture capital and private equity firm investing in biotechnology companies.

Sr One is a venture capital and private equity firm investing in biotechnology companies that is headquartered in Cambridge, Massachusetts and was founded in 1985 as the sub-organization of GlaxoSmithKline. Sr One has invested over $830 million invested in the biotechnology space.

Investments

Sr One invests in pre-clinical, clinical, and commercial stage biotechnology companies. Notable investments made by Sr One include: Atopix, Alios BioPharma, NuPathe, Concert Pharmaceuticals, Gotham Therapeutics, Illuminoss, TP Therapeutics, ProtAffin, CRISPR Therapeutics, Arcellx, Adheron Therapeutics, Pulmocide, Second Genome, Sumprus Biosciences, Propeller, VHsquared, Nimbus Therapeutics, AGTC, and Constellation Pharmaceuticals.

Their exited investments include CRISPR Therapeutics, Progyny, Propeller Health, Genocea Biosciences, Bicycle Therapeutics, Dicerna Pharmaceuticals, Turning Point Therapeutics, ZappRx, Morphic Therapeutic, Translate Bio and Spero Therapeutics.

Timeline

Funded Companies

Company
Description
Industry
Website
Location
Decibel Therapeutics

Decibel Therapeutics conducts inner ear research to deliver medicines for hearing and balance.

Nkarta Therapeutics is a biotechnology company using natural killer (NK) immune cells for cellular therapies.

A biotechnology company discovering drugs that target the epitranscriptomics machinery that modifies RNA.

Avantium Technologies is an Amsterdam-based manufacturing company offering research and development for products and applications in the energy, chemicals, and pharmaceuticals industry.

MISSION Therapeutics is a Cambridge, Cambridgeshire-based biotechnology company offering a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes.

Propeller Health is a Madison, Wisconsin-based company offering sensors, mobile apps, analytics and services to support respiratory health management.

A biopharmaceutical company dedicated to the development of novel therapeutics in the field of Epigenetics

Pandion Therapeutics is a Cambridge, Massachusetts-based company developing modular proteins, antibodies and bispecifics for autoimmune and inflammatory diseases.

A biopharmaceutical company developing oral small molecule therapies for the treatment of cancer and autoimmune diseases

F-star is a Cambridge, Cambridgeshire-based company founded in 2006.

A company dedicated on the discovery and development of small molecule therapeutics to treat cancer

A biotechnology company developing medicines to treatment viral diseases

ZappRx is a Cambridge, Massachusetts-based health information technology company founded in 2012.

Palleon Pharmaceuticals is a Waltham, Massachusetts-based company.

Dren Bio, Inc. is a San Carlos, California-based company.

IlluminOss Medical is a East Providence, Rhode Island-based healthcare company founded by Arnold Peter Weiss.

PsiOxus Therapeutics is an Oxfordshire-based company founded in 2006 by Kerry Fisher.

TP Therapeutics is a San Diego-based company founded in 2013.

Applied Genetic Technologies Corporation is an Alachua, Florida-based company.

Pulmocide is a London-based company.

Macrolide Pharmaceuticals is a Watertown, Massachusetts-based company.

27 Results
Results per page:
Page 1 of 2

People

Name
Role
LinkedIn

David Madden

Advisor

Imogen Mansfield

Employee

Jens Eckstein

Employee

Joyce A Lonergan

Employee

Rehan Mirza

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
FinSMEs
November 24, 2020
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Alex Keown
November 19, 2020
BioSpace
Venture capital firm SR One, founded in 1985 as the venture capital arm of pharma giant GlaxoSmithKline, completed its spinout from its parent company and closed its first independent fun at $500 million.
Amirah Al Idrus
November 19, 2020
FierceBiotech
SR One has backed biotech companies for decades as GlaxoSmithKline's venture arm. Now, the firm is striking out on its own, having spun out from the British conglomerate and raised a whopping $500 million fund. The fund, SR One's first, will back "elite" biotechs on both sides of the Atlantic, working on new medicines to address treatment gaps.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.